Oncology Interviews ↓

Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?

John S. Macdonald MD FACP

John S. Macdonald MD FACP

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor status to the choice of molecular therapy for patients with metastatic colorectal cancer. Whether the gene is wild-type or mutant determines sensitivity of the tumor to anti-epidermal growth factor or anti-vascular endothelial growth factor receptor therapy. Dr Macdonald also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.

Chronic Myeloid Leukemia ‘To Become A Very Indolent Disease’: Pregnancy Possible, Transplants Avoided—Mission Accomplished?

Hagop Kantarjian MD

Hagop Kantarjian MD

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Hagop Kantarjian MD from the MD Anderson Cancer Center in Houston about his latest findings on treating CML in patients who have the T315I mutation. He also discusses the feasibility of patients becoming pregnant while having tyrosine kinase inhibitor (TKI) treatment (among those who have achieved stability for at least two years); and talks about the decreased need for allogeneic transplant.

Global Health Interviews ↓


Click Here for All Global Health Interviews
Subscribe to Audio Medica Podcast